Marker Therapeutics Excess Tax Benefit from Stock Compensation (Quarterly) Analysis

Marker Therapeutics, Inc. (MRKR)

1.48 -0.10 (-6.33%) USD | NASDAQ | Feb 27, 16:00

1.48 0.00 (0.00%) After-Hours: 20:00

View Excess Tax Benefit from Stock Compensation (Quarterly) for MRKR.
Upgrade now.

Sep '18

Jan '19

May '19

285.00

270.00

255.00

240.00

View Excess Tax Benefit from Stock Compensation (Quarterly) Chart

Start Trial

View Historical Data

Start Trial

View Excess Tax Benefit from Stock Compensation (Quarterly) Range, Past 5 Years

Start Trial

Minimum

Maximum

Average

Median

View Excess Tax Benefit from Stock Compensation (Quarterly) Benchmarks

Start Trial

ADMA Biologics, Inc.	--
Viridian Therapeutics, Inc.	--
ACADIA Pharmaceuticals, Inc.	--
Kiniksa Pharmaceuticals International Plc	--
Neurocrine Biosciences, Inc.	--